Growth hormone isoforms

Growth Hormone and IGF Research

Volumn 19, Issue 4, 2009, Pages 333-340

  Baumann, Gerhard P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Growth hormone; Isoforms; Molecular variants; Somatotrophin

Indexed keywords

GROWTH HORMONE; ISOPROTEIN; MESSENGER RNA; PLACENTA LACTOGEN;

ACYLATION; ARTICLE; CHROMOSOME 17Q; COVALENT BOND; DEAMINATION; DISULFIDE BOND; GENE CLUSTER; GENETIC HETEROGENEITY; GENOME ANALYSIS; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE ACTION; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE STRUCTURE; HUMAN; HYPOTHALAMUS; IMMUNOASSAY; IMMUNOREACTIVITY; MATERNAL BLOOD; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; RNA SPLICING; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; URINE LEVEL;

AMINO ACID SEQUENCE; BIOLOGICAL ASSAY; CHROMOSOME MAPPING; DIMERIZATION; GLYCOSYLATION; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; PITUITARY GLAND; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RNA, MESSENGER;

EID: 67651165030     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.04.011     Document Type: Article

References (119)

1. Chen E.Y., Liao Y.C., Smith D.H., Barrera-Saldana H.A., Gelinas R.E., and Seeburg P.H. The human growth hormone locus: nucleotide sequence. Biol. Evolut. Genomics 4 (1989) 479-497
2. DeNoto F.M., Moore D.D., and Goodman H.M. Human growth hormone DNA sequence and mRNA structure: possible alternative splicing. Nucleic Acids Res. 9 (1981) 3719-3730
3. Lecomte C.M., Renard A., and Martial J.A. A new natural hGH variant - 17.5 kDa - produced by alternative splicing. An additional consensus sequence which might play a role in branchpoint selection. Nucleic Acids Res. 15 (1987) 6331-6348
4. Cooke N.E., Ray J., Watson M.A., Estes P.A., Kuo B.A., and Liebhaber S.A. Human growth hormone gene and the highly homologous growth hormone variant gene display different splicing patterns. J. Clin. Invest. 82 (1988) 270-275
5. Palmetshofer A., Zechner D., Luger T.A., and Barta A. Splicing variants of the human growth hormone mRNA: detection in pituitary. Mononuclear cells and dermal fibroblasts. Mol. Cell Endocrinol. 113 (1995) 225-234
6. Boguszewski C.L., Svensson P.A., Jansson T., Clark R., Carlsson L.M., and Carlsson B. Cloning of two novel growth hormone transcripts expressed in human placenta. J. Clin. Endocrinol. Metab. 83 (1998) 2878-2885
7. Liebhaber S.A., Urbanek M., Ray J., Tuan R.S., and Cooke N.E. Characterization and histologic localization of human growth hormone-variant gene expression in the placenta. J. Clin. Invest. 83 (1989) 1985-1991
8. Li C.H., and Papkoff H. Preparation and properties of growth hormone from human and monkey pituitary glands. Science 124 (1956) 1293-1294
9. Niall H.D. Revised primary structure for human growth hormone. Nat. New Biol. 230 (1971) 90-91
10. Lewis U.J., Dunn J.T., Bonewald L.F., Seavey B.K., and Vanderlaan W.P. A naturally occurring structural variant of human growth hormone. J. Biol. Chem. 253 (1978) 2679-2687
11. Lewis U.J., Singh R.N., Bonewald L.F., Lewis L.J., and Vanderlaan W.P. Human growth hormone: additional members of the complex. Endocrinology 104 (1979) 1256-1265
12. Lewis U.J., Singh R.N., Bonewald L.F., and Seavey B.K. Altered proteolytic cleavage of human growth hormone as a result of deamidation. J. Biol. Chem. 256 (1981) 11645-11650
13. Haro L.S., Lewis U.J., Garcia M., Bustamante J., Martinez A.O., and Ling N.C. Glycosylated human growth hormone (hGH): a novel 24 kDa hGH-N variant. Biochem. Biophys. Res. Commun. 228 (1996) 549-556
14. Baumann G. Growth hormone heterogeneity: genes. Isohormones, variants, and binding proteins. Endocrinol. Rev. 12 (1991) 424-449
15. Canova-Davis E., Baldonado I.P., Moore J.A., Rudman C.G., Bennett W.F., and Hancock W.S. Properties of a cleaved two-chain form of recombinant human growth hormone. Int. J. Pept. Protein Res. 35 (1990) 17-24
16. Gellerfors P., Pavlu B., Axelsson K., Nyhlen C., and Johansson S. Separation and identification of growth hormone variants with high performance liquid chromatography techniques. Acta Paediatr. Scand. Suppl. 370 (1990) 93-100
17. Ultsch M.H., Somers W., Kossiakoff A.A., and de Vos A.M. The crystal structure of affinity-matured human growth hormone at 2A resolution. J. Mol. Biol. 236 (1994) 286-299
18. Chapman G.E., et al. The 20,000 molecular weight variant of human growth hormone. Preparation and some physical and chemical properties. J. Biol. Chem. 256 (1981) 2395-2401
19. Lewis U.J., Peterson S.M., Bonewald L.F., Seavey B.K., and VanderLaan W.P. An interchain disulfide dimer of human growth hormone. J. Biol. Chem. 252 (1977) 3697-3702
20. Brostedt P., and Roos P. Isolation of dimeric forms of human pituitary growth hormone. Prep. Biochem. 19 (1989) 217-229
21. Grigorian A.L., Bustamante J.J., Hernandez P., Martinez A.O., and Haro L.S. Extraordinarily stable disulfide-linked homodimer of human growth hormone. Protein Sci. 14 (2005) 902-913
22. Frankenne F., Scippo M.L., Van Beeumen J., Igout A., and Hennen G. Identification of placental human growth hormone as the growth hormone-V gene expression product. J. Clin. Endocrinol. Metab. 71 (1990) 15-18
23. Ray J., Jones B.K., Liebhaber S.A., and Cooke N.E. Glycosylated human growth hormone variant. Endocrinology 125 (1989) 566-568
24. Singh R.N.P., Seavey B.K., Lewis L.J., and Lewis U.J. Human growth hormone peptide 1-43: isolation from pituitary glands. J. Protein Chem. 2 (1983) 425-436
25. Salem M.A., and Wolff G.L. Potentiation of response to insulin and anti-insulin action by two human pituitary peptides in lean agouti A/a, obese yellow Avy/A, and C57BL/6J-ob/ob mice. Proc. Soc. Exp. Biol. Med. 191 (1989) 113-123
26. Sinha Y.N., and Jacobsen B.P. Human growth hormone (hGH)-(44-191). A reportedly diabetogenic fragment of hGH, circulates in human blood: measurement by radioimmunoassay. J. Clin. Endocrinol. Metab. 78 (1994) 1411-1418
27. Frigeri L.G., Peterson S.M., and Lewis U.J. The 20,000-dalton structural variant of human growth hormone: lack of some early insulin-like effects. Biochem. Biophys. Res. Commun. 91 (1979) 778-782
28. Lewis U.J., Singh R.N., and Tutwiler G.F. Hyperglycemic activity of the 20,000-dalton variant of human growth hormone. Endocrinol. Res. Commun. 8 (1981) 155-164
29. Kostyo J.L., Cameron C.M., Olson K.C., Jones A.J., and Pai R.C. Biosynthetic 20-kilodalton methionyl-human growth hormone has diabetogenic and insulin-like activities. Proc. Natl. Acad. Sci. USA 82 (1985) 4250-4253
30. Ader M., Agajanian T., Finegood D.T., and Bergman R.N. Recombinant deoxyribonucleic acid-derived 22K- and 20K-human growth hormone generate equivalent diabetogenic effects during chronic infusion in dogs. Endocrinology 120 (1987) 725-731
31. Takahashi S., Shiga Y., Satozawa N., and Hayakawa M. Diabetogenic activity of 20 kDa human growth hormone (20K-hGH) and 22K-hGH in rats. Growth Horm. IGF Res. 11 (2001) 110-116
32. Kostyo J.L., et al. Biological characterization of purified native 20-kDa human growth hormone. Biochim. Biophys. Acta 925 (1987) 314-324
33. Uchida H., et al. Secretion of authentic 20-kDa human growth hormone (20K hGH) in Escherichia coli and properties of the purified product. J. Biotechnol. 55 (1997) 101-112
34. Ishikawa M., Tachibana T., Kamioka T., Horikawa R., Katsumata N., and Tanaka T. Comparison of the somatogenic action of 20 kDa- and 22 kDa-human growth hormones in spontaneous dwarf rats. Growth Horm. IGF Res. 10 (2000) 199-206
35. Takahashi S., and Satozawa N. The 20-kD human growth hormone reduces body fat by increasing lipolysis and decreasing lipoprotein lipase activity. Horm. Res. 58 (2002) 157-164
36. Campbell R.M., Kostyo J.L., and Scanes C.G. Lipolytic and antilipolytic effects of human growth hormone, its 20-kilodalton variant. A reduced and carboxymethylated derivative, and human placental lactogen on chicken adipose tissue in vitro. Proc. Soc. Exp. Biol. Med. 193 (1990) 269-273
37. Wada M., et al. The full agonistic effect of recombinant 20 kDa human growth hormone (hGH) on CHO cells stably transfected with hGH receptor cDNA. Mol. Cell Endocrinol. 133 (1997) 99-107
38. Tsunekawa B., Wada M., Ikeda M., Uchida H., Naito N., and Honjo M. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor. Endocrinology 140 (1999) 3909-3918
39. Asada N., et al. GH induced lipolysis stimulation in 3T3-L1 adipocytes stably expressing hGHR: analysis on signaling pathway and activity of 20K hGH. Mol. Cell Endocrinol. 162 (2000) 121-129
40. Solomon G., Reicher S., Gussakovsky E.E., Jomain J.B., and Gertler A. Large-scale preparation and in vitro characterization of biologically active human placental (20 and 22K) and pituitary (20K) growth hormones: placental growth hormones have no lactogenic activity in humans. Growth Horm. IGF Res. 16 (2006) 297-307
41. Hayakawa M., et al. Metabolic effects of 20-kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH. J. Clin. Endocrinol. Metab. 89 (2004) 1562-1571
42. Hashimoto Y., et al. Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. J. Clin. Endocrinol. Metab. 85 (2000) 601-606
43. Momomura S., Hashimoto Y., Shimazaki Y., and Irie M. Detection of exogenous growth hormone (GH) administration by monitoring ratio of 20 kDa- and 22 kDa-GH in serum and urine. Endocrinol. J. 47 (2000) 97-101
44. Wallace J.D., et al. Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males. J. Clin. Endocrinol. Metab. 86 (2001) 1731-1737
45. Leung K.C., Howe C., Gui L.Y., Trout G., Veldhuis J.D., and Ho K.K. Physiological and pharmacological regulation of 20-kDa growth hormone. Am. J. Physiol. Endocrinol. Metab. 283 (2002) E836-E843
46. Keller A., et al. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur. J. Endocrinol. 156 (2007) 647-653
47. Sigel M.B., Thorpe N.A., Kobrin M.S., Lewis U.J., and Vanderlaan W.P. Binding characteristics of a biologically active variant of human growth hormone (20K) to growth hormone and lactogen receptors. Endocrinology 108 (1981) 1600-1603
48. Smal J., Closset J., Hennen G., and de Meyts P. Receptor-binding and down-regulatory properties of 22000-Mr human growth hormone and its natural 20000-Mr variant on IM-9 human lymphocytes. Biochem. J. 225 (1985) 283-289
49. Smal J., Closset J., Hennen G., and De Meyts P. Receptor binding properties and insulin-like effects of human growth hormone and its 20 kDa-variant in rat adipocytes. J. Biol. Chem. 262 (1987) 11071-11079
50. McCarter J., Shaw M.A., Winer L.A., and Baumann G. The 20,000 Da variant of human growth hormone does not bind to growth hormone receptors in human liver. Mol. Cell Endocrinol. 73 (1990) 11-14
51. Ikeda M., et al. Cellular activities of 20K- and 22K-hGH do not necessarily correlate with their binding affinities for rat GH receptor. Horm. Res. 54 (2000) 136-142
52. Baumann G., Stolar M.W., Amburn K., Barsano C.P., and DeVries B.C. A specific growth hormone-binding protein in human plasma: initial characterization. J. Clin. Endocrinol. Metab. 62 (1986) 134-141
53. Baumann G., and Shaw M.A. Plasma transport of the 20,000-dalton variant of human growth hormone (20K): evidence for a 20K-specific binding site. J. Clin. Endocrinol. Metab. 71 (1990) 1339-1343
54. Hansen B.S., Hjorth S., Welinder B.S., Skriver L., and De Meyts P. The growth hormone (GH)-binding protein cloned from human IM-9 lymphocytes modulates the down-regulation of GH receptors by 22- and 20-kilodalton human GH in IM-9 lymphocytes and the biological effects of the hormone in Nb2 lymphoma cells. Endocrinology 133 (1993) 2809-2817
55. Wada M., et al. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma. Mol. Endocrinol. 12 (1998) 146-156
56. Baumann G., Stolar M.W., and Buchanan T.A. Slow metabolic clearance rate of the 20,000-dalton variant of human growth hormone: implications for biological activity. Endocrinology 117 (1985) 1309-1313
57. Tsunekawa B., et al. The binding between the stem regions of human growth hormone (GH) receptor compensates for the weaker site 1 binding of 20-kDa human GH (hGH) than that of 22-kDa hGH. J. Biol. Chem. 275 (2000) 15652-15656
58. Skottner A., et al. Biological characterization of charge isomers of human growth hormone. Acta Endocrinol. (Copenh) 118 (1988) 14-21
59. Ikeda M., Wada M., Fujita Y., Takahashi S., Maekawa K., and Honjo M. A novel bioassay based on human growth hormone (hGH) receptor mediated cell proliferation: measurement of 20K-hGH and its modified forms. Growth Horm. IGF Res. 10 (2000) 248-255
60. MacLeod J.N., Worsley I., Ray J., Friesen H.G., Liebhaber S.A., and Cooke N.E. Human growth hormone-variant is a biologically active somatogen and lactogen. Endocrinology 128 (1991) 1298-1302
61. Igout A., Frankenne F., L'Hermite-Baleriaux M., Martin A., and Hennen G. Somatogenic and lactogenic activity of the recombinant 22 kDa isoform of human placental growth hormone. Growth Regul. 5 (1995) 60-65
62. Goodman H.M., Tai L.R., Ray J., Cooke N.E., and Liebhaber S.A. Human growth hormone variant produces insulin-like and lipolytic responses in rat adipose tissue. Endocrinology 129 (1991) 1779-1783
63. Selden R.F., Wagner T.E., Blethen S., Yun J.S., Rowe M.E., and Goodman H.M. Expression of the human growth hormone variant gene in cultured fibroblasts and transgenic mice. Proc. Natl. Acad. Sci. USA 85 (1988) 8241-8245
64. Barbour L.A., et al. Human placental growth hormone causes severe insulin resistance in transgenic mice. Am. J. Obstet. Gynecol. 186 (2002) 512-517
65. Ray J., Okamura H., Kelly P.A., Cooke N.E., and Liebhaber S.A. Human growth hormone-variant demonstrates a receptor binding profile distinct from that of normal pituitary growth hormone. J. Biol. Chem. 265 (1990) 7939-7944
66. Baumann G., Davila N., Shaw M.A., Ray J., Liebhaber S.A., and Cooke N.E. Binding of human growth hormone (GH)-variant (placental GH) to GH-binding proteins in human plasma. J. Clin. Endocrinol. Metab. 73 (1991) 1175-1179
67. Moore W.V. The role of aggregated hGH in therapy of hGH-deficient children. J. Clin. Endocrinol. Metab. 46 (1978) 20-27
68. Mockridge J.W., Aston R., Morrell D.J., and Holder A.T. Cross-linked growth hormone dimers have enhanced biological activity. Eur. J. Endocrinol. 138 (1998) 449-459
69. Yang N., Langenheim J.F., Wang X., Jiang J., Chen W.Y., and Frank S.J. Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering. Mol. Endocrinol. 22 (2008) 978-988
70. Guyda J.H. Heterogeneity of human growth hormone and prolactin secreted in vitro: immunoassay and radioreceptor assay correlations. J. Clin. Endocrinol. Metab. 41 (1975) 953-967
71. Wright D.R., Goodman A.D., and Trimble K.D. Studies on "big" growth hormone from human plasma and pituitary. J. Clin. Invest. 54 (1974) 1064-1073
72. Gorden P., Lesniak M.A., Hendricks C.M., and Roth J. "Big" growth hormone components from human plasma: decreased reactivity demonstrated by radioreceptor assay. Science 182 (1973) 829-831
73. Nagatomi Y., et al. Reversible dimerization of 20 kDa human growth hormone (hGH). Growth Horm. IGF Res. 10 (2000) 207-214
74. Yuki Y., and Kato K. A 22 kDa human growth hormone specific enzyme-linked immunosorbent assay. Biol. Pharm. Bull. 17 (1994) 977-979
75. Mellado M., Rodriguez-Frade J.M., Kremer L., and Martinez-Alonso C. Characterization of monoclonal antibodies specific for the human growth hormone 22K and 20K isoforms. J. Clin. Endocrinol. Metab. 81 (1996) 1613-1618
76. Hashimoto Y., et al. Construction of a specific and sensitive sandwich enzyme immunoassay for 20 kDa human growth hormone. J. Immunol. Methods 221 (1998) 77-85
77. Evain-Brion D., Alsat E., Igout A., Frankenne F., and Hennen G. Placental growth hormone variant: assay and clinical aspects. Acta Paediatr. 1 399 (1994) 49-51 discussion 52
78. Wu Z., et al. A new nonisotopic, highly sensitive assay for the measurement of human placental growth hormone: development and clinical implications. J. Clin. Endocrinol. Metab. 88 (2003) 804-811
79. Boguszewski C.L., Hynsjo L., Johannsson G., Bengtsson B.A., and Carlsson L.M. 22-kD growth hormone exclusion assay: a new approach to measurement of non-22-kD growth hormone isoforms in human blood. Eur. J. Endocrinol. 135 (1996) 573-582
80. Wu Z., Bidlingmaier M., Dall R., and Strasburger C.J. Detection of doping with human growth hormone. Lancet 353 (1999) 895
81. Popii V., and Baumann G. Laboratory measurement of growth hormone. Clin. Chim. Acta 350 (2004) 1-16
82. Bidlingmaier M., and Strasburger C.J. Growth hormone assays: current methodologies and their limitations. Pituitary 10 (2007) 115-119
83. Baumann G., Stolar M.W., and Buchanan T.A. The metabolic clearance, distribution, and degradation of dimeric and monomeric growth hormone (GH): implications for the pattern of circulating GH forms. Endocrinology 119 (1986) 1497-1501
84. Fairhall K.M., Carmignac D.F., and Robinson I.C. Growth hormone (GH) binding protein and GH interactions in vivo in the guinea pig. Endocrinology 131 (1992) 1963-1969
85. Wallace J.D., et al. The response of molecular isoforms of growth hormone to acute exercise in trained adult males. J. Clin. Endocrinol. Metab. 86 (2001) 200-206
86. Hendricks C.M., Eastman R.C., Takeda S., Asakawa K., and Gorden P. Plasma clearance of intravenously administered pituitary human growth hormone: gel filtration studies of heterogeneous components. J. Clin. Endocrinol. Metab. 60 (1985) 864-867
87. Lonberg U., et al. Increase in maternal placental growth hormone during pregnancy and disappearance during parturition in normal and growth hormone-deficient pregnancies. Am. J. Obstet. Gynecol. 188 (2003) 247-251
88. Fuglsang J., Sandager P., Moller N., Fisker S., Orskov H., and Ovesen P. Kinetics and secretion of placental growth hormone around parturition. Eur. J. Endocrinol. 154 (2006) 449-457
89. Baumann G. Metabolic clearance rates of isohormones of human growth hormone in man. J. Clin. Endocrinol. Metab. 49 (1979) 495-499
90. Vahl N., Moller N., Lauritzen T., Christiansen J.S., and Jorgensen J.O. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J. Clin. Endocrinol. Metab. 82 (1997) 3612-3618
91. Frohman L.A., Burek L., and Stachura M.A. Characterization of growth hormone of different molecular weights in rat. Dog Human Pituitaries, Endocrinol. 91 (1972) 262-269
92. Talamantes F., Lopez J., Lewis U.J., and Wilson C.B. Multiple forms of growth hormone: detection in medium from cultured pituitary adenoma explants. Acta Endocrinol. (Copenh) 98 (1981) 8-13
93. Baumann G., and MacCart J.G. Growth hormone production by human pituitary glands in organ culture: evidence for predominant secretion of the single-chain 22,000 molecular weight form (isohormone B). J. Clin. Endocrinol. Metab. 55 (1982) 611-618
94. Markoff E., Lee D.W., Culler F.L., Jones K.L., and Lewis U.J. Release of the 22,000- and the 20,000-dalton variants of growth hormone in vivo and in vitro by human anterior pituitary cells. J. Clin. Endocrinol. Metab. 62 (1986) 664-669
95. Murakami Y., et al. Twenty-kilodalton human growth hormone (20K hGH) secretion from growth hormone-secreting pituitary adenoma cells in vitro. Endocrinol. J. 47 (2000) 563-568
96. Baumann G., and Stolar M.W. Molecular forms of human growth hormone secreted in vivo: nonspecificity of secretory stimuli. J. Clin. Endocrinol. Metab. 62 (1986) 789-790
97. Tsushima T., et al. Serum concentration of 20K human growth hormone (20K hGH) measured by a specific enzyme-linked immunosorbent assay. Study Group of 20K hGH. J. Clin. Endocrinol. Metab. 84 (1999) 317-322
98. Eriksson L., Frankenne F., Eden S., Hennen G., and Von Schoultz B. Growth hormone 24-h serum profiles during pregnancy - lack of pulsatility for the secretion of the placental variant. Br. J. Obstet. Gynaecol. 96 (1989) 949-953
99. Frankenne F., Closset J., Gomez F., Scippo M.L., and Hennen G. The physiology of growth hormones (GHs) in pregnant women and partial characterisation of the placental GH variant. J. Clin. Endocrinol. Metab. 66 (1988) 1171-1180
100. Chellakooty M., et al. A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. J. Clin. Endocrinol. Metab. 89 (2004) 384-391
101. Hennen G., Frankenne F., Closset J., Gomez F., Pirens G., and El Khayat N. A human placental GH: increasing levels during second half of pregnancy with pituitary GH suppression as revealed by monoclonal antibody radioimmunoassays. Int. J. Fertil. 30 (1985) 27-33
102. Bala R.M., Ferguson K.A., and Beck J.C. Plasma biological and immunoreactive human growth hormone-like activity. Endocrinology 87 (1970) 506-516
103. Goodman A.D., Tanenbaum R., and Rabinowitz D. Existence of two forms of immunoreactive growth hormone in human plasma. J. Clin. Endocrinol. Metab. 35 (1972) 868-878
104. Baumann G., MacCart J.G., and Amburn K. The molecular nature of circulating growth hormone in normal and acromegalic man: evidence for a principal and minor monomeric forms. J. Clin. Endocrinol. Metab. 56 (1983) 946-952
105. Baumann G., Stolar M.W., and Amburn K. Molecular forms of circulating growth hormone during spontaneous secretory episodes and in the basal state. J. Clin. Endocrinol. Metab. 60 (1985) 1216-1220
106. Stolar M.W., Baumann G., Vance M.L., and Thorner M.O. Circulating growth hormone forms after stimulation of pituitary secretion with growth hormone-releasing factor in man. J. Clin. Endocrinol. Metab. 59 (1984) 235-239
107. Stolar M.W., Amburn K., and Baumann G. Plasma "big" and "big-big" growth hormone (GH) in man: an oligomeric series composed of structurally diverse GH monomers. J. Clin. Endocrinol. Metab. 59 (1984) 212-218
108. Baumann G. Growth hormone binding protein 2001. J. Pediatr. Endocrinol. Metab. 14 (2001) 355-375
109. Baumann G., Amburn K., and Shaw M.A. The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man. Endocrinology 122 (1988) 976-984
110. Baumann G., Vance M.L., Shaw M.A., and Thorner M.O. Plasma transport of human growth hormone in vivo. J. Clin. Endocrinol. Metab. 71 (1990) 470-473
111. Veldhuis J.D., Johnson M.L., Faunt L.M., Mercado M., and Baumann G. Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications. J. Clin. Invest. 91 (1993) 629-641
112. Ishikawa M., et al. Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children. J. Clin. Endocrinol. Metab. 84 (1999) 98-104
113. Svensson J., Boguszewski C.L., Shibata F., Carlsson B., Carlsson L.M., and Bengtsson B.A. The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms. Growth Hormone IGF Res. 13 (2003) 1-7
114. Boguszewski C.L., et al. Circulating non-22 kDa growth hormone isoforms in healthy children of normal stature: relation to height, body mass and pubertal development. Eur. J. Endocrinol. 137 (1997) 246-253
115. Boguszewski C.L., et al. Increased proportion of circulating non-22-kilodalton growth hormone isoforms in short children: a possible mechanism for growth failure. J. Clin. Endocrinol. Metab. 82 (1997) 2944-2949
116. Baumann G., and Abramson E.C. Urinary growth hormone in man: evidence for multiple molecular forms. J. Clin. Endocrinol. Metab. 56 (1983) 305-311
117. Winer L.M., Shaw M.A., and Baumann G. Urinary growth hormone excretion rates in normal and acromegalic man: a critical appraisal of its potential clinical utility. J. Endocrinol. Invest. 12 (1989) 461-467
118. Gill M.S., Toogood A.A., O'Neill P.A., Thorner M.O., Shalet S.M., and Clayton P.E. Urinary growth hormone (GH), insulin-like growth factor I (IGF-I), and IGF-binding protein-3 measurements in the diagnosis of adult GH deficiency and IGF-binding protein-3 measurements in the diagnosis of adult GH deficiency. J. Clin. Endocrinol. Metab. 83 (1998) 2562-2565
119. Hanssen K.F. Immunoreactive growth hormone in human urine. Acta Endocrinol. (Copenh) 71 (1972) 665-676